Rucaparib

Generic Name: Rucaparib

Brand Names: Rubraca

Drug Type: Small Molecule

Chemical Formula: C_₁₉H_₁₈FN_₃O

CAS Number: 283173-50-2

Unique Ingredient Identifier: 8237F3U7EH

Background: Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the genetically-mutated cancer cells that la...

Indication: Rucaparib is indicated for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)- associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.
...

Associated Conditions: Metastatic Castration-Resistant Prostate Cancer (mCRPC), Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer

Associated Therapies: Maintenance therapy

Clinical Trials

Rucaparib Plus Ramucirumab With or Without Nivolumab in Advanced Gastric and Esophageal Adenocarcinoma

Phase 1

Active, not recruiting

Conditions: Stomach Cancer, Adenocarcinoma
Esophagus Cancer, Adenocarcinoma

Interventions: Drug: Rucaparib
Drug: Ramucirumab
Drug: Nivolumab

First Posted Date: 2019-06-21

Last Posted Date: 2023-02-01

Lead Sponsor: University of Kansas Medical Center

Target Recruit Count: 34

Registration Number: NCT03995017

Locations: 🇺🇸
University of Kansas Cancer Center - Lee's Summit, Lee's Summit, Missouri, United States
🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸
KU Cancer Center, Fairway, Kansas, United States

and more 5 locations

A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)

Phase 1

Terminated

Conditions: Triple-negative Breast Cancer
Ovarian Cancer
Urothelial Carcinoma
Solid Tumor

Interventions: Drug: Rucaparib
Drug: Lucitanib
Drug: Sacituzumab govitecan

First Posted Date: 2019-06-20

Last Posted Date: 2024-01-16

Lead Sponsor: pharmaand GmbH

Target Recruit Count: 25

Registration Number: NCT03992131

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States

Drug-Drug Interaction Study of Rucaparib, Rosuvastatin and Oral Contraceptives

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: Rucaparib
Drug: Oral Contraceptives
Drug: Rosuvastatin

First Posted Date: 2019-05-17

Last Posted Date: 2023-06-08

Lead Sponsor: pharmaand GmbH

Target Recruit Count: 36

Registration Number: NCT03954366

Locations: 🇵🇱
Zdrowie Kobiety Centrum Leczniczo-Rehabilitacyjne i Medycyny Pracy ATTIS Sp. z o.o., Zakład Onkologii Kobiecej, Warszawa, Poland
🇸🇰
Summit Clinical Research s.r.o., Bratislava, Slovakia
🇭🇺
PRA Magyarország Fázis I-es Klinikai Farmakológiai Vizsgálóhely FMC Dialízis Központ, II. em., Budapest, Hungary

and more 4 locations

Window of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast Tumors

Early Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: Rucaparib

First Posted Date: 2019-04-11

Last Posted Date: 2024-10-03

Lead Sponsor: University of Arizona

Target Recruit Count: 20

Registration Number: NCT03911453

Locations: 🇺🇸
University of Arizona Cancer Center, Tucson, Arizona, United States

Pan Tumor Rollover Study

First Posted Date: 2019-04-02

Last Posted Date: 2024-11-19

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 1500

Registration Number: NCT03899155

Locations: 🇧🇷
Local Institution - 0260, Belo Horizonte, Minas Gerais, Brazil
🇨🇳
Harbin Medical University - Cancer Hospital, Harbin, Heilongjiang, China
🇨🇳
Local Institution - 0172, Changsha, Hunan, China

and more 304 locations

Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

Phase 2

Active, not recruiting

Conditions: Deleterious BRCA1 Gene Mutation
Recurrent Large Cell Lung Carcinoma
Deleterious BRCA2 Gene Mutation
Recurrent Lung Adenocarcinoma
Recurrent Non-Squamous Non-Small Cell Lung Carcinoma
Stage IV Lung Cancer AJCC v8
Loss of Heterozygosity
Lung Non-Small Cell Squamous Carcinoma
Stage IVA Lung Cancer AJCC v8
Stage IVB Lung Cancer AJCC v8

Interventions: Drug: Rucaparib

First Posted Date: 2019-02-19

Last Posted Date: 2024-12-20

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 64

Registration Number: NCT03845296

Locations: 🇺🇸
Mount Carmel East Hospital, Columbus, Ohio, United States
🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
Grady Health System, Atlanta, Georgia, United States

and more 944 locations

A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.

Phase 1

Completed

Conditions: Breast Cancer
Prostate Cancer
Ovarian Cancer

Interventions: Drug: Ipatasertib
Drug: Rucaparib

First Posted Date: 2019-02-15

Last Posted Date: 2023-10-30

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 51

Registration Number: NCT03840200

Locations: 🇦🇺
Macquarie University Hospital, Macquarie Park, New South Wales, Australia
🇪🇸
Clínica Universidad de Navarra, Pamplona, Navarra, Spain
🇮🇹
Azienda Ospedaliera Santa Maria di Terni, Terni, Umbria, Italy

and more 14 locations

A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)

Phase 2

Terminated

Conditions: Epithelial Ovarian Cancer
Primary Peritoneal Carcinoma
High Grade Serous Carcinoma
Endometrioid Adenocarcinoma
Fallopian Tube Cancer

Interventions: Drug: Rucaparib
Drug: Nivolumab

First Posted Date: 2019-01-31

Last Posted Date: 2023-06-12

Lead Sponsor: pharmaand GmbH

Target Recruit Count: 1

Registration Number: NCT03824704

Locations: 🇺🇸
Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
🇺🇸
Community Cancer Institute, Clovis, California, United States
🇺🇸
Memorial Health University Medical Center, Savannah, Georgia, United States

and more 2 locations

Rucaparib Maintenance Therapy in Advanced Cervical Cancer

Phase 2

Withdrawn

Conditions: Cervical Cancer

Interventions: Drug: Rucaparib
Drug: Placebo

First Posted Date: 2019-01-07

Last Posted Date: 2019-11-01

Lead Sponsor: Nordic Society of Gynaecological Oncology - Clinical Trials Unit

Registration Number: NCT03795272

Locations: 🇩🇰
Rigshospitalet, København Ø, Sjaelland, Denmark

A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study

Phase 3

Recruiting

Conditions: Cancer

Interventions: Drug: Atezolizumab
Drug: Cobimetinib
Drug: Bevacizumab
Drug: Vemurafenib
Drug: Alectinib
Drug: Pembrolizumab
Drug: FAP IL2V
Drug: Sunitinib
Drug: Venetoclax
Drug: Enzalutamide
Drug: Paclitaxel
Drug: Niraparib
Drug: Cabozantinib
Drug: Pemetrexed
Drug: Emactuzumab
Drug: Rucaparib

First Posted Date: 2018-12-07

Last Posted Date: 2024-12-20

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 1000

Registration Number: NCT03768063

Locations: 🇺🇸
Univ of Alabama at Birmingham; UAB Comprehensive Cancer Ctr, Birmingham, Alabama, United States
🇺🇸
HonorHealth Research Institute - Pima - Virginia G. Piper Cancer Care Network, Scottsdale, Arizona, United States
🇺🇸
University of Arkansas for Medical Sciences; Winthrop Rockefeller Cancer Institute, Little Rock, Arkansas, United States

and more 199 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy